{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-044434","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2024-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.052398+00:00","generated_at":"2026-05-30T09:41:38.071325+00:00","sec_items":["1.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Roivant subsidiary Dermavant acquired by Organon; merger closed Oct 28, 2024","bullets":["Organon completed acquisition of Dermavant from Roivant on October 28, 2024, expanding dermatology portfolio.","VTAMA (tapinarof) cream 1% is FDA-approved for plaque psoriasis; sNDA for atopic dermatitis under review with PDUFA in Q4 2024.","Dermavant's credit agreement terminated upon closing; all amounts outstanding repaid.","Roivant President cites win-win outcome; expects to share meaningfully in VTAMA's success via collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-044434","json":"https://secwatch.observer/filing/0001140361-24-044434.json","markdown":"https://secwatch.observer/filing/0001140361-24-044434.md","text":"https://secwatch.observer/filing/0001140361-24-044434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124044434/0001140361-24-044434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124044434/ef20037790_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:41:38.071325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}